Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)

Core Viewpoint - Defence Therapeutics Inc. is set to license its proprietary Accum® technology to pharmaceutical and biotech companies developing Antibody Drug Conjugates (ADCs), aiming to enhance ADC potency and reduce dosing requirements [3][4]. Group 1: Company Overview - Defence Therapeutics is a Canadian biopharmaceutical company focused on developing radiopharmaceuticals and ADC products, alongside novel immune-oncology vaccines [3][9]. - The company's Accum® technology is designed to improve the delivery and efficacy of biologics, particularly in oncology and immunotherapy applications, by overcoming endosomal entrapment [4][9]. Group 2: Business Model and Strategy - The licensing of Accum® technology is expected to generate immediate revenue while establishing the technology as an industry standard in ADC development [5]. - Defence plans to expand the applications of Accum® into other therapeutic areas, including radiopharmaceuticals, vaccines, and protein-based treatments, ensuring a sustainable revenue model that balances short-term profitability with long-term innovation [5]. Group 3: Financial Activities - The company recently closed a non-brokered private placement, issuing 50,000 units at a price of $0.50 per unit, raising gross proceeds of $25,000, which will be used to advance preclinical and clinical programs [6]. - An amendment was made to the terms of 1,497,780 Class A Common share purchase warrants, reducing the exercise price from $1.75 to $0.75 per share [7].